Cite
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
MLA
Radominski, Sebastião Cezar, et al. “Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Latin American Patients with Rheumatoid Arthritis: Pooled Efficacy and Safety Analyses of Phase 3 and Long-Term Extension Studies.” Reumatología Clínica, vol. 13, no. 4, July 2017, pp. 201–09. EBSCOhost, https://doi.org/10.1016/j.reuma.2016.04.010.
APA
Radominski, S. C., Cardiel, M. H., Citera, G., Goecke, A., Jaller, J. J., Vannucci Lomonte, A. B., Miranda, P., Velez, P., Xibillé, D., Kwok, K., Rojo, R., & García, E. G. (2017). Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies. Reumatología Clínica, 13(4), 201–209. https://doi.org/10.1016/j.reuma.2016.04.010
Chicago
Radominski, Sebastião Cezar, Mario Humberto Cardiel, Gustavo Citera, Annelise Goecke, Juan Jose Jaller, Andrea Barranjard Vannucci Lomonte, Pedro Miranda, et al. 2017. “Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Latin American Patients with Rheumatoid Arthritis: Pooled Efficacy and Safety Analyses of Phase 3 and Long-Term Extension Studies.” Reumatología Clínica 13 (4): 201–9. doi:10.1016/j.reuma.2016.04.010.